Patents (1325 Stem Cell Patents)

Patents

Order by:
<< | < | 124 125 126 127 128 129 130 131 132 | > | >>


Homologous recombination for universal donor cells and chimeric mammalian hosts

Patent Number: 5413923

This patent teaches how to genetically delete the MHC antigens in order to have stem cells and progeny of the stem cells that are capable of acting as universal donor cells. Although this technology is at face value very interesting, the fact that other antigens besides MHC cause rejection of tissue dampens enthusiasm for this approach...

Inventors: Kucherlapati, Raju (Darien, CT); Koller, Beverly H. (Carrboro, NC); Smithies, Oliver (Chapel Hill, NC)
Assignee: Cell Genesys, Inc. (Foster City, CA) Univ. of North Carolina at Chapel Hill (Chapel Hill, NC)
Date of First Priority Issue: Monday November 6th, 1989

Expansion of human hematopoietic progenitor cells in a liquid medium

Patent Number: 5409825

This patent uses mast cell growth factor as an additive to tissue culture media in order to generate a liquid composition that is useful for expansion of hematopoietic stem cells. The ability of this media to expand other types of stem cells should be assessed.

Inventors: Hoffman, Ronald (Indianapolis, IN); Brandt, John (Indianapolis, IN)
Assignee: None stated
Date of First Priority Issue: Tuesday April 9th, 1991

Medium for long-term proliferation and development of cells

Patent Number: 5405772

This patent is for a tissue culture media that is capable of expanding, as well as allowing differentiation of various cell types in vitro, including hematopoietic stem cells. The media is different than other approaches since it comprises several growth factors, as well as extracellular matrix components. Importantly the media does not use serum, this is applicable for clinical ex vivo...

Inventor: Ponting, Ian L. O. (Woodland Hills, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday June 18th, 1993

Methods and compositions for the optimization of human hematopoietic progenitor cell cultures

Patent Number: 5399493

The genetic engineering of hematopoietic stem cells offers the potential to cure several disease, including severe combined immunodeficiency, sickle cell anemia, beta thalessemia, etc. This patent teaches how to ex vivo genetically engineer hematopoietic stem cells through the use of retroviral vectors. This patent is highly cited by other patents.

Inventors: Emerson, Stephen G. (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Palsson, Bernhard O. (Ann Arbor, MI); Schwartz, Richard M. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989

Serum-free basal and culture medium for hematopoietic and leukemia cells

Patent Number: 5397706

This patent teaches the making of a serum free media for growth hematopoietic stem cells. Such a media is useful since the addition of fetal serum and especially fetal calf serum in culture medium for cell therapy is associated with regulatory hurdles.

Inventors: Correa, Paulo N. (Concord, Ontario, CA); Alexrad, Arthur A. (Willowdale, Ontario, CA)
Assignee: Not Stated
Date of First Priority Issue: Wednesday November 6th, 1991

Ketamine analogues for treatment of thrombocytopenia

Patent Number: 5384331

Ketamine is used as an anasthetic in veterinary medicine, as well as for some human uses. This patent teaches various chemical modifications of ketamine that stimulate production of stem cells that are committed to generating platelets. The importance of stimulating platelet production is seen by the number of companies working on either thrombopoietin analogues or antibodies to the...

Inventors: Kogan, Timothy P. (Half Moon Bay, CA); Somers, Todd C. (Montara, CA)
Assignee: Genentech, Inc. (San Francisco, CA)
Date of First Priority Issue: Thursday July 18th, 1991

Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs

Patent Number: 5369030

Ceramides are generated from membrane components by the enzyme sphingomyelinase. The importance of ceramides in cell biology is noted by their pro-apoptotic activity in certain cells, as well as ability to induce differentiation. This patent teaches that certain ceramides may be used to guide differentiation of stem cells into various lineages. It may be possible the through taking the...

Inventors: Hannun, Yusuf A. (Chapel Hill, NC); Bielawska, Alicja (Apex, NC)
Assignee: Duke University (Durham, NC)
Date of First Priority Issue: Friday September 11th, 1992

Method of regenerating articular cartilage

Patent Number: 5368051

This patent teaches how to use growth hormone, as well as other factors for the repair of articular cartilage. The method is useful for developing not only therapeutic kits, but also as a stepping stop for new methods of using stem cells, both endogenous and exogeneous in cartilage repair.

Inventors: Dunn, Allan R. (North Miami, FL); Dunn, Susan L. (North Miami, FL)
Assignee: Non Stated
Date of First Priority Issue: Wednesday June 30th, 1993

Enhanced maintenance of pregnancy using leukaemia inhibitory factor in embryo culturing

Patent Number: 5366888

This patent is assigned to Amrad, a company whose patents have recently been used to challenge the WARF patents. The current patent involves the use of LIF in enhancing ability of implanted embryos to develop into normal offspring. The relevance of this patent to embryonic stem cells is that LIF has been used...

Inventors: Fry, Richard C. (Altona North, AU); Parr, Ronald A. (Hoppers Crossing, AU)
Assignee: Amrad Corporation Limited (AU)
Date of First Priority Issue: Monday July 9th, 1990

Polypeptide derivatives of human granulocyte colony stimulating factor

Patent Number: 5362853

G-CSF is used clinically for stimulation of neutrophil production in pateints that have taken chemotherapy, radiation therapy (in some cases), as well as post bone marrow tranplant. This patent covers peptide derivatives of G-CSF that are useful for stimulation of hematopoiesis. It may be interesting to use this patent to compete with currently used G-CSF formulations.

Inventors: Kuga, Tetsuro (Yamaguchi, JP); Miyaji, Hiromasa (Tokyo, JP); Sato, Moriyuki (Tokyo, JP); Okabe, Masami (Shizuoka, JP); Morimoto, Makoto (Shizuoka, JP); Itoh, Seiga (Kanagawa, JP); Yamasaki, Motoo (Tokyo, JP); Yokoo, Yoshiharu (Kanagawa, JP); Yamaguchi, Ka
Assignee: Kyowa Hakko Kogyo Co., Ltd. (Tokyo, JP)
Date of First Priority Issue: Tuesday December 23rd, 1986

Order by:
<< | < | 124 125 126 127 128 129 130 131 132 | > | >>




Home | News | Patents | Products | Journal | Jobs | Search | RSS

About | Advisory Board | Newsletter | Advertise | Contact | Sitemap | Privacy Policy | Terms of Use

Copyright © 2006 - 2008 StemCellPatents.com - All rights reserved. - Toronto Web Design

StemCellPatents.com V2.03